Loading...
XNAS
TECH
Market cap9.96bUSD
Dec 04, Last price  
63.54USD
1D
-0.44%
1Q
16.78%
Jan 2017
147.17%
Name

Bio-Techne Corp

Chart & Performance

D1W1MN
XNAS:TECH chart
P/E
135.70
P/S
8.17
EPS
0.47
Div Yield, %
0.38%
Shrs. gr., 5y
0.27%
Rev. gr., 5y
10.55%
Revenues
1.22b
+5.23%
202,617,000223,482,000257,420,000263,956,000269,047,000289,962,000314,560,000310,575,000357,763,000452,246,000499,023,000563,003,000642,993,000714,006,000738,691,000931,032,0001,105,599,0001,136,702,0001,159,060,0001,219,635,000
Net income
73m
-56.34%
73,351,00085,111,000103,558,000105,242,000109,776,000112,302,000112,331,000112,561,000110,948,000107,735,000104,476,00077,286,000125,350,00096,072,000229,296,000140,410,000272,051,000285,263,000168,105,00073,400,000
CFO
288m
-3.82%
85,589,00090,503,000115,317,000111,321,000111,260,000127,194,000126,746,000123,562,000136,762,000139,359,000143,870,000143,448,000170,367,000181,619,000205,217,000352,164,000325,272,000254,393,000298,981,000287,556,000
Dividend
Aug 19, 20240.08 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
IPO date
Feb 09, 1989
Employees
3,050
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT